Improvement of Sorafenib on Recent Quality of Life for Patients with Terminal-stage Hepatocellular Carcinoma

Objective To explore the improvement of sorafenib treatment on the recent quality of life for patients with terminal-stage hepatocellular carcinoma after three months. Methods We investigated the quality of life of 36 patients with oral sorafenib by the Quality of Life Questionnaire-C30(QLQ-C30) V3.0 of EORTC. The quality of life before and 3 months after the treatment was analyzed. Results There were signifi cant difference among physical status, fatigue, nausea and vomiting, pain, constipation, diarrhea and economic diffi culties(P<0.05) but the overall quality of life had no obvious improvement.